Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Ascendis Pharma A/s: which funds own it

Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow for free
Share

Sections with a free account

1 concentrated manager holds it; combined they have held more shares for 2 quarters in a row (1 added, 0 trimmed). Its median weight in those portfolios is 1.3%.

Who owns Ascendis Pharma A/s?

Ascendis Pharma A/s trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): T. Rowe Price Investment Management, 10.5% (13G/A filed May 7, 2026), Westfield Capital Management, 8.5% (13G/A filed Feb 11, 2026), FMR, 8.0% (13G/A filed May 12, 2025), Janus Henderson Group, 6.0% (13G/A filed May 15, 2026) and Artisan Partners Limited Partnership, 5.2% (13G/A filed Feb 3, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Frazier Life Sciences Management (225,155 ADRs), Neuberger Berman Group (142,705 ADRs) and Oddo BHF Asset Management SAS (128,657 ADRs).

Which institutions hold the most Ascendis Pharma A/s shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. Frazier Life Sciences Management: 225,155 ADRs
  2. 2. Neuberger Berman Group: 142,705 ADRs
  3. 3. Oddo BHF Asset Management SAS: 128,657 ADRs
  4. 4. Quadrature Capital: 40,845 ADRs
  5. 5. Ferguson Wellman Capital Management: 2,600 ADRs
  6. 6. Dearborn Partners: 1,300 ADRs
  7. 7. E Fund Management (Hong Kong): 84 ADRs
  8. 8. Ninepoint Partners: 26 ADRs
  9. 9. IFP Advisors: 14 ADRs
  10. 10. Huntington National Bank: 1 ADRs

Sources:13G/A by T. Rowe Price Investment Management (May 7, 2026) ↗13G/A by Westfield Capital Management (Feb 11, 2026) ↗13G/A by FMR (May 12, 2025) ↗13G/A by Janus Henderson Group (May 15, 2026) ↗13G/A by Artisan Partners Limited Partnership (Feb 3, 2026) ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
1
All 13F: 10
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$266.72
+16.6% in the quarter · reported value ÷ shares, not the quote

Quarter flow (concentrated managers)

Change in managers (1 → 1): 0 opened · 0 exited = 0

Net flow in the quarter: +$24.5M (+92 K shares) · bought $24.5M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Accumulation: combined they have held more shares for 2 quarters in a row (1 added, 0 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.

The set of concentrated managers changed between quarters: with the set as it was then, 16 held it last quarter (the chart point); with today's set, 1 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Insiders (Form 4)

Officers and directors who bought (6 m)
no data
Amount (6 m)
no data
CEO/CFO bought (12 m)
No

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market.

Follow Ascendis Pharma A/s for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow Ascendis Pharma A/s